Jack Greenberg to Serve as Chairman
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles Founder Dr. Dennis Gillings, CBE, will retire from his
position as Executive Chairman of Quintiles Transnational Holdings Inc.
(NYSE: Q) at the end of this year, December 31, 2015. Dr. Gillings will
remain on the Board as a director. The Board has appointed Jack M.
Greenberg to serve as Chairman of the Board, effective January 1, 2016.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20151105006951/en/
Dennis Gillings, CBE, Quintiles Founder (Photo: Business Wire)
Dr. Gillings began performing biostatical analysis work for
pharmaceutical companies with a single project in 1974 while still a
professor of biostatistics at the University of North Carolina at Chapel
Hill. That small consulting business, which would become Quintiles,
began with a handful of staff working out of a trailer on the UNC campus.
Quintiles was incorporated as a privately held company in 1982, and over
the past 33 years, has grown from that small collection of statisticians
and college students into the world’s largest provider of
biopharmaceutical services, a FORTUNE 500 company with nearly 35,000
employees conducting business in 100 countries.
Dr. Gillings took Quintiles public through its first Initial Public
Offering (IPO) in 1994, and then led a leveraged buyout to take the
company private again in 2003. Quintiles remained a private company for
10 years until its second IPO in 2013. Gillings served as Quintiles CEO
for nearly all of the company’s first 30 years of operation until
current CEO Tom Pike joined the company in 2012.
During Dr. Gillings’ tenure with the company, Quintiles began its
international expansion in 1987 and moved into clinical drug development
in 1988 and commercialization services in 1996. Just 16 years after
incorporation, Quintiles recorded more than $1 billion (USD) in service
revenue. In 2014, the company earned $4.2 billion in service revenue.
“Quintiles grew very quickly and consistently from its beginnings in
1982,” Gillings remarked. “It has been a memorable ride to get to our
multi-billion dollar status today, and I feel privileged to have led
this journey. However, I believe there is so much more to come,” he
continued. “I wish Tom and our management team great success navigating
our next era of opportunities so that patients are able to access
fast-moving medical advances more easily, timely and cost effectively.
Thank you, employees for making all this possible.”
Quintiles CEO Tom Pike noted Gillings’ continuing importance to
Quintiles. “There would be no Quintiles without Dennis Gillings,” Pike
said. “The vision that Dennis displayed in the early years of Quintiles
led to a revolution in the way drug development is conducted. He truly
was truly a pioneer in the emergence of the clinical research
organization (CRO) industry.
“Dennis recognized that a company such as Quintiles could become a true
partner with its biopharmaceutical customers rather than a task manager,
and provide a plethora of value-added services from product development
and commercialization to advisory, regulatory and real-world, late phase
services. We are proud to have him as our founder, and will continue to
seek his guidance as he continues his work with the Quintiles Board,”
Pike concluded.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies
improve their probability of success by connecting insights from our
deep scientific, therapeutic and analytics expertise with superior
delivery for better outcomes. From advisory through operations,
Quintiles is the world’s largest provider of product development and
integrated healthcare services, including commercial and observational
solutions. Conducting operations in approximately 100 countries,
Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s
list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here
to subscribe to Mobile Alerts for Quintiles.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105006951/en/
Source: Quintiles